Novartis Plea On Cancer Drug Patent Rejected By India’s Supreme Court
This article was originally published in PharmAsia News
Executive Summary
Novartis AG lost an appeal before India's Supreme Court for patent protection on its blockbuster tyrosine kinase inhibitor Gleevec/Glivec (imatinib), an outcome the company said before the decision would adversely impact its plans for India.